Lifecore Biomedical
LFCR
80 hedge funds and large institutions have $115M invested in Lifecore Biomedical in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 15 closing their positions.
58% more call options, than puts
Call options by funds: $778K | Put options by funds: $492K
37% more capital inflows, than outflows
Capital inflows: $10.8M | Capital outflows: $7.87M
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
1% more funds holding
Funds holding: 79 → 80 (+1)
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0.63% more ownership
Funds ownership: 70.13% → 70.76% (+0.63%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cove Street Capital
El Segundo,
California
|
+$2.67M |
| 2 |
Jane Street
New York
|
+$1.14M |
| 3 |
272 Capital
Dallas,
Texas
|
+$1.04M |
| 4 |
325 Capital
New York
|
+$956K |
| 5 |
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$678K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
-$1.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.19M |
| 3 |
BlackRock
New York
|
-$862K |
| 4 |
Defender Capital
Charlotte,
North Carolina
|
-$535K |
| 5 |
Union Square Park Capital Management
New York
|
-$429K |
LFCR Hedge Fund Activity: Q1 2024 in Review
80 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2024, worth a combined $115M — down 13% from $132M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LFCR positions and 15 closed out — a net gain of 1 holder — while 25 added to existing stakes and 19 trimmed.
The largest buyer was Cove Street Capital, adding an estimated $2.67M. The largest seller was Greenhaven Road Investment Management, cutting an estimated $1.59M.
- 80 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2024, up from 79 in Q4 2023.
- Funds reported $115M of Lifecore Biomedical stock for Q1 2024, down 13% quarter-over-quarter.
- 16 funds opened new Lifecore Biomedical positions in Q1 2024 and 15 closed out, a net change of +1 holder.
- The largest Lifecore Biomedical buyer in Q1 2024 was Cove Street Capital, an estimated $2.67M added.
- The largest Lifecore Biomedical seller in Q1 2024 was Greenhaven Road Investment Management, an estimated $1.59M sold.
Based on aggregated 13F filings for Q1 2024.